A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

International Journal of Hematology

Volumn 70, Issue 1, 1999, Pages 20-25

  Takemoto, Yoshinobu ^a   Sampi, Kazumi ^b   Kuraishi, Yasunobu ^c   Okabe, Kenichi ^d   Tamura, Kazuo ^e   Mizoguchi, Hideaki ^f   Saito, Hidehiko ^g   Masaoka, Tohru ^h   Ogawa, Makoto ⁱ  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Shiraoi Town Hospital   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute myelogenous leukemia; Complete remission; Cytosine arabinoside; Daunorubicin; KRN8602; Randomized trial

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CARUBICIN; CYTARABINE; DAP PROTOCOL; DAUNORUBICIN; DRUG DERIVATIVE; MORPHOLINOANTHRACYCLINE MX2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARUBICIN; CENTRAL NERVOUS SYSTEM DISEASES; CYTARABINE; DAUNORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033159405     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Komeshima N, Turuo T, Umezawa H. Antitumor activity of new morpholino anthracyclines. J Antibiot 1988;41:548-53.
2. Watanabe M, Komeshima N, Nakajima S, et al. MX2, a morpholino anthracycline, as a new antitumor agent against drug sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 1988;48:6653-7.
3. Sato Y, Eddy L, Hochstein P. Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochem Pharmacol 1991;42:2283-7.
4. Tabata M, Ogawa M, Horikoshi N, et al. Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline. Jpn J Cancer Chemother 1989;7:2361-6.
5. Takemoto Y, Sanpi K, Kuraishi Y, et al. Early phase II study of KRN8602 (MX-2). A novel anthracycline derivative for acute leukemia. Jpn J Cancer Chemother 1998;25:2243-8.
6. Hiraoka A, Sanpi K, Kuraishi Y, et al. Pilot late phase II study of KRN 8602 (MX-2). A novel anthracycline derivative for acute leukemia: a dose finding study in combination therapy. Jpn J Cancer Chemother 1999;26:93-9.
7. Kimura K. Chemotherapy of acute leukemia with special reference to criteria for evaluation of therapeutic effect. Proceedings, Advances in Chemotherapy of Acute Leukemia. A seminar on chemotherapy of acute leukemia under the US-Japan cooperative science program, Bethesda, Maryland, September 27-28, 1965:21.
8. The response criteria for solid tumor with chemotherapy by Japan Society of Cancer Chemotherapy [in Japanese]. J Jpn Soc Cancer Ther 1986;21:929-53.
9. Yamamoto H, Arita N, Ohnishi T, et al. Pharmacokinetics of MX-2, a new morpholino anthracycline, in CSF following intravenous injection. Jpn J Cancer Chemother 1993;9:1227-30.
10. Kiya K, Ogasawara H, Fujita H, et al. Pharmacokinetics and antitumor activity of MX-2, a new morpholino anthracycline, in rats with brain tumors transplanted intracerebrally Jpn J Cancer Chemother 1993;5:631-5.